Immunological treatment options for schizophrenia

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1606-1613

  Müller, Norbert ^a   Myint, Aye Mu ^a   Schwarz, Markus J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

COX 2 inhibition; Inflammation; Psychoneuroimmunology; Schizophrenia; Therapy

Indexed keywords

AMISULPRIDE; CELECOXIB; IMMUNOMODULATING AGENT; KYNURENINE; NEUROLEPTIC AGENT; OLANZAPINE; RECOMBINANT ERYTHROPOIETIN; RISPERIDONE; TETRACYCLINE; TRYPTOPHAN;

ADD ON THERAPY; AMINO ACID METABOLISM; ARTICLE; DISEASE COURSE; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; NONHUMAN; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; ASTROCYTES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; KYNURENINE; MICROGLIA; SCHIZOPHRENIA; TRYPTOPHAN;

EID: 84862615959     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784826     Document Type: Article

References (87)

1. Shi, J.; Levinson, D.F.; Duan, J.; Sanders, A.R.; Zheng, Y.; Pe'er, I.; Dudbridge, F.; Holmans, P.A.; Whittemore, A.S.; Mowry, B.J.; Olincy, A.; Amin, F.; Cloninger, C.R.; Silverman, J.M.; Buccola, N.G.; Byerley, W.F.; Black, D.W.; Crowe, R.R.; Oksenberg, J.R.; Mirel, D.B.; Kendler, K.S.; Freedman, R.; Gejman, P.V. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature, 2009, 460(7256), 753-757.
2. Stefansson, H.; Ophoff, R.A.; Steinberg, S.; Andreassen, O.A.; Cichon, S.; Rujescu, D.; Werge, T.; Pietiläinen, O.P.; Mors, O.; Mortensen, P.B.; Sigurdsson, E.; Gustafsson, O.; Nyegaard, M.; Tuulio-Henriksson, A.; Ingason, A.; Hansen, T.; Suvisaari, J.; Lonnqvist, J.; Paunio, T.; Børglum, A.D.; Hartmann, A.; Fink- Jensen, A.; Nordentoft, M.; Hougaard, D.; Norgaard-Pedersen, B.; Böttcher, Y.; Olesen, J.; Breuer, R.; Möller, H.J.; Giegling, I.; Rasmussen, H.B.; Timm, S.; Mattheisen, M.; Bitter, I.; Réthelyi, J.M.; Magnusdottir, B.B.; Sigmundsson, T.; Olason, P.; Masson, G.; Gulcher, J.R.; Haraldsson, M.; Fossdal, R.; Thorgeirsson, T.E.; Thorsteinsdottir, U.; Ruggeri, M.; Tosato, S.; Franke, B.; Strengman, E.; Kiemeney, L.A.; Genetic Risk and Outcome in Psychosis (GROUP); Melle, I.; Djurovic, S.; Abramova, L.; Kaleda, V.; Sanjuan, J.; de Frutos, R.; Bramon, E.; Vassos, E.; Fraser, G.; Ettinger, U.; Picchioni, M.; Walker, N.; Toulopoulou, T.; Need, A.C.; Ge, D.; Yoon, J.L.; Shianna, K.V.; Freimer, N.B.; Cantor, R.M.; Murray, R.; Kong, A.; Golimbet, V.; Carracedo, A.; Arango, C.; Costas, J.; Jönsson, E.G.; Terenius, L.; Agartz, I.; Petursson, H.; Nöthen, M.M.; Rietschel, M.; Matthews, P.M.; Muglia, P.; Peltonen, L.; St Clair, D.; Goldstein, D.B.; Stefansson, K.; Collier, D.A. Common variants conferring risk of schizophrenia. Nature, 2009, 460(7256), 744-747.
3. Purcell, S.M.; Wray, N.R.; Stone, J.L.; Visscher, P.M.; O'Donovan, M.C.; Sullivan, P.F. Sklar, P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature, 2009, 460(7256), 748-752.
4. Costa, E.; Dong, E.; Grayson, D.R.; Guidotti, A.; Ruzicka, W.; Veldic, M. Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics, 2007, 2(1), 29-36.
5. Kawasaki, H.; Iwamuro, S. Potential roles of histones in host defense as antimicrobial agents. Infect. Disord. Drug. Targets, 2008, 8(3), 195-205.
6. Fellerhoff, B.; Laumbacher, B.; Mueller, N.; Gu, S.; Wank, R. Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10. Mol. Psychiatry, 2007, 12(3), 264-272.
7. Zuckerman, L.; Weiner, I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J. Psychiatr. Res., 2005, 39(3), 311-323.
8. Winter, C.; Djodari-Irani, A.; Sohr, R.; Morgenstern, R.; Feldon, J.; Juckel, G.; Meyer, U. Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int. J. Neuropsychopharmacol., 2009, 12(4), 513-524.
9. Brown, A.S. Prenatal infection as a risk factor for schizophrenia. Schizophr. Bull., 2006, 32(2), 200-202.
10. Swerdlow, N.R.; van Bergeijk, D.P.; Bergsma, F.; Weber, E.; Talledo, J. The Effects of Memantine on Prepulse Inhibition. Neuropsychopharmacology, 2009, 34(7), 1854-1864.
11. Müller, N.; Schwarz, M.J. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J. Neurotransmission, 2007, (Suppl. 72), 269-280.
12. Müller, N.; Schwarz, M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry, 2007, 1-13.
13. Mills, C.D.; Kincaid, K.; Alt, J.M.; Heilman, M.J.; Hill, A.M. M- 1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol., 2000, 164(12), 6166-6173.
14. Kim, Y.K.; Myint, A.M.; Verkerk, R.; Scharpe, S.; Steinbusch, H.; Leonard, B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology, 2009, 59(2), 123-129.
15. Brown, A.S.; Begg, M.D.; Gravenstein, S.; Schaefer, C.A.; Wyatt, R.J.; Bresnahan, M.; Babulas, V.P.; Susser, E.S. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch. Gen. Psychiatry, 2004, 61(8), 774-780.
16. Buka, S.L.; Goldstein, J.M.; Seidman, L.J.; Tsuang, M.T. Maternal recall of pregnancy history: accuracy and bias in schizophrenia research. Schizophr. Bull., 2000, 26(2), 335-350.
17. Gattaz, W.F.; Abrahao, A.L.; Foccacia, R. Childhood meningitis, brain maturation and the risk of psychosis. Eur. Arch. Psychiatry Clin. Neurosci., 2004, 254(1), 23-26.
18. Koponen, H.; Rantakallio, P.; Veijola, J.; Jones, P.; Jokelainen, J.; Isohanni, M. Childhood central nervous system infections and risk for schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2004, 254(1), 9-13.
19. Brown, A.S. The risk for schizophrenia from childhood and adult infections. Am. J. Psychiatry, 2008, 165(1), 7-10.
20. Dalman, C.; Allebeck, P.; Gunnell, D.; Harrison, G.; Kristensson, K.; Lewis, G.; Lofving, S.; Rasmussen, F.; Wicks, S.; Karlsson, H. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am. J. Psychiatry, 2008, 165(1), 59-65.
21. Körschenhausen, D.A.; Hampel, H.J.; Ackenheil, M.; Penning, R.; Müller N. Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr. Res., 1996, 19(2/3), 103-109.
22. Bechter, K. Mild encephalitis underlying psychiatric disorders - A reconsideration and hypothesis exemplified on Borna disease. Neurol. Psychiatry Brain Res., 2001, 9, 55-70.
23. Wilke, I.; Arolt, V.; Rothermundt, M.; Weitzsch, C.; Hornberg, M.; Kirchner, H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci., 1996, 246(5), 279-284.
24. Müller, N.; Riedel, M.; Ackenheil, M.; Schwarz, M.J. Cellular and humoral immune system in schizophrenia: a conceptual reevaluation. World J. Biol. Psychiatry, 2000, 1(4), 173-179.
25. Sperner-Unterweger, B.; Miller, C.; Holzner, B.; Widner, B.; Fleischhacker, W.W.; Fuchs, D. In: Psychoimmunology, and viruses; Müller, N. Ed.; Psychiatry, Springer:, Wien, New York, 1999; 115-119.
26. Müller, N.; Ackenheil, M.; Hofschuster, E.; Mempel, W.; Eckstein, R. Cellular immunity in schizophrenic patients before and during neuroleptic treatment. Psychiatry Res, 1991, 37(2), 147-160.
27. Schwarz, M.J.; Riedel, M.; Ackenheil, M.; Müller, N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry, 2000, 47(1), 29-33.
28. Haack, M.; Hinze-Selch, D.; Fenzel, T.; Kraus, T.; Kuhn, M.; Schuld, A.; Pollmächer, T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res., 1999, 33(5), 407-418.
29. Molholm, H.B. Hyposensitivity to foreign protein in schizophrenic patients. Psychiatr. Quarterly, 1942, 16:565-571.
30. Riedel, M.; Spellmann, I.; Schwarz, M.J.; Strassnig, M.; Sikorski, C.; Möller, H.J.; Müller, N. Decreased T cellular immune response in schizophrenic patients. J. Psychiatr. Res., 2007, 41(1/2), 3-7.
31. Bresee, C.; Rapaport, M.H. Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. Int. J. Neuropsychopharmacol., 2009, 12(6), 861-865.
32. Potvin, S.; Stip, E.; Sepehry, A.A.; Gendron, A.; Bah, R.; Kouassi, E. Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review. Biol. Psychiatry, 2008, 63(8), 801-808.
33. Cazzullo, C.L.; Scarone, S.; Grassi, B.; Vismara, C.; Trabattoni, D.; Clerici, M.; Clerici, M. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1998, 22(6), 947-957.
34. Lin, A.; Kenis, G.; Bignotti, S.; Tura, G.J.; De Jong, R.; Bosmans, E.; Pioli, R.; Altamura, C.; Scharpé, S.; Maes, M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res., 1998, 32(1), 9-15.
35. Sperner-Unterweger, B.; Whitworth, A.; Kemmler, G.; Hilbe, W.; Thaler, J.; Weiss, G.; Fleischhacker, W.W. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr. Res., 1999, 38(1), 61-70.
36. Schwarz, M.J.; Chiang, S.; Müller, N.; Ackenheil, M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun., 2001, 15(4), 340-370.
37. van Kammen, D.P.; McAllister-Sistilli, C.G.; Kelley, M.E. In: Current Update in Psychoimmunology; Wieselmann, G. Ed.; Springer: Wien, New York, 1997; 51-55.
38. Mittleman, B.B., Castellanos, F.X.; Jacobsen, L.K.; Rapoport, J.L.; Swedo, S.E.; Shearer, G.M. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J. Immunol., 1997, 159(6), 2994-2999.
39. Müller, N.; Riedel, M.; Schwarz, M.J.; et al. In: Wieselmann G Ed, Current update in psychoimmunology. Wien, New York, Springer, 1997, 57-67.
40. Müller, N.; Empl, M.; Riedel, M.; Schwarz, M.; Ackenheil, M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 1997, 247(6), 308-313.
41. Müller, N.; Riedel, M.; Hadjamu, M.; Schwarz, M.J.; Ackenheil, M.; Gruber, R. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am. J. Psychiatry, 1999, 156(4), 634-636.
42. Pollmächer, T.; Schuld, A.; Kraus, T.; Haack, M.; Hinze-Selch, D. On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors. Fortschr. Neurol. Psychiatr., 2001, 69 (Suppl. 2), S65-74.
43. Ozek, M.; Toreci, K.; Akkok, I.; Guvener, Z. Influence of therapy on antibody-formation. Psychopharmacologia, 1971, 21(4), 401-412.
44. Tanaka, K.F.; Shintani, F.; Fujii, Y.; Yagi, G.; Asai, M. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res., 2000, 96(1), 75-80.
45. Maes, M.; Bosmans, E.; De Jongh, R.; Kenis, G., Vandoolaeghe, E.; Neels, H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine, 1997, 9(11), 853-858.
46. Aloisi, F.; Penna, G.; Cerase, J.; Menendez, I.B.; Adorini, L. IL-12 production by central nervous system microglia is inhibited by astrocytes. J. Immunol., 1997, 159(4), 1604-1612.
47. Rothermundt, M.; Falkai, P.; Ponath, G., Abel, S.; Burkle, H.; Diedrich, M.; Hetzel, G.; Peters, M.; Siegmund, A.; Pedersen, A.; Maier, W.; Schramm, J.; Suslow, T.; Ohrmann, P.; Arolt, V. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry, 2004, 9(10), 897-899.
48. Bayer, T.A.; Buslei, R.; Havas, L.; Falkai, P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett., 1999, 271(2), 126-128.
49. van Berckel, B.N.; Bossong, M.G.; Boellaard, R.; Kloet, R.; Schuitemaker, A.; Caspers, E.; Luurtsema, G.; Windhorst, A.D.; Cahn, W.; Lammertsma, A.A.; Kahn, R.S. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry, 2008, 64(9), 820-822.
50. Heyes, M.P.; Chen, C.Y.; Major, E.O.; Saito, K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem. J., 1997, 326(pt 2), 351-356.
51. Kiss, C.; Ceresoli-Borroni, G.; Guidetti, P.; Zielke, C.L.; Zielke, H.R.; Schwarcz, R. Kynurenate production by cultured human astrocytes. J. Neural. Transm., 2003, 110(1), 1-14.
52. Guillemin, G.J.; Kerr, S.J.; Smythe, G.A.; Smith, D.G.; Kapoor, V.; Armati, P.J.; Croitoru, J.; Brew, B.J. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem., 2001, 78(4), 842-853.
53. Chiarugi, A.; Carpenedo, R.; Moroni, F. Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase. J. Neurochem., 1996, 67(2), 692-698.
54. Wagner von Jauregg, J. Fieberbehandlung bei Psychosen. Wien Med Wochenschr 1926, 76, 79-82.
55. Müller, N.; Schwarz, M.J.; Riedel, M. In: Medical and psychiatric comorbidity over the course of life; Eaton, W.W., Ed.; American Psychiatric Publishing: Washington D.C., 2005, pp. 265-276.
56. Ross, B.M.; Seguin, J.; Sieswerda, L.E. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis., 2007, 6, 21.
57. Amminger, G.P.; Schafer, M.R.; Papageorgiou, K.; Klier, C.M.; Cotton, S.M.; Harrigan, S.M.; Mackinnon, A.; McGorry, P.D.; Berger, G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry, 2010, 67(2), 146-154.
58. Ehrenreich, H.; Hinze-Selch, D.; Stawicki, S.; Aust, C.; Knolle- Veentjer, S.; Wilms, S.; Heinz, G.; Erdag, S.; Jahn, H.; Degner, D.; Ritzen, M.; Mohr, A.; Wagner, M.; Schneider, U.; Bohn, M.; Huber, M.; Czernik, A.; Pollmächer, T.; Maier, W.; Sirén, A.L.; Klosterkötter, J.; Falkai, P.; Rüther, E.; Aldenhoff, J.B.; Krampe, H. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol. Psychiatry, 2007, 12(2), 206-220.
59. Wüstenberg, T.; Begemann, M.; Bartels, C.; Gefeller, O.; Stawicki, S.; Hinze-Selch, D.; Mohr, A.; Falkai, P.; Aldenhoff, J.B.; Knauth, M.; Nave, K.A.; Ehrenreich, H. Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol. Psychiatry, 2011, 16(1), 26-36.
60. Chaves, C.; Marque, C.R.; Chaudhry, I.B.; Hussain, F.M.; Oliveira, J.P.; Wichert-Ana, L. Short-term improvement by minocycline added to olanzapine antipsychotic treatment in paranoid schizophrenia. Schizophr. Bull., 2009, 354(Suppl. 1).
61. Ahuja, N.; Carroll, B.T. Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(4), 968-969.
62. Mizoguchi, H.; Takuma, K.; Fukakusa, A., Ito, Y.; Nakatani, A.; Ibi, D.; Kim, H.C.; Yamada, K. Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl.), 2008, 196(2), 233-241.
63. Dickerson, F.B.; Boronow, J.J.; Stallings, C.R.; Origoni, A.E. Yolken, R.H. Reduction of symptoms by valacyclovir in cytomegalovirus- seropositive individuals with schizophrenia. Am. J. Psychiatry, 2003, 160(12), 2234-2236.
64. Dickerson, F.B.; Stallings, C.R.; Boronow, J.J.; Origoni, A.E.; Sullens, A.; Yolken, R.H. Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus. Schizophr. Res., 2009, 107(2-3), 147-149.
65. Dickerson, F.B.; Stallings, C.R.; Boronow, J.J.; Origoni, A.E.; Yolken, R.H. A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii. Schizophr. Res., 2009, 112(1-3), 198-199.
66. Schwieler, L.; Erhardt, S.; Erhardt, C.; Engberg, G. Prostaglandinmediated control of rat brain kynurenic acid synthesis--opposite actions by COX-1 and COX-2 isoforms. J. Neural. Transm., 2005, 112(7), 863-872.
67. Müller, N.; Riedel, M.; Scheppach, C.; Brandstätter, B.; Sokullu, S.; Krampe, K.; Ulmschneider, M.; Engel, R.R.; Möller, H.J.; Schwarz, M.J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry, 2002, 159(6), 1029-1034.
68. Müller, N.; Riedel, M.; Dehning, S.; Spellmann, I.; Müller-Arends, A.; Cerovecki, A.; et al. Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease? Neuropsychopharmacology, 2004, 29(1), 176.
69. Müller, N.; Ulmschneider, M.; Scheppach, C.; Schwarz, M.J.; Ackenheil, M.; Möller, H.J.; Gruber, R.; Riedel, M. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur. Arch. Psychiatry Clin. Neurosci., 2004, 254(1), 14-22.
70. Casolini, P.; Catalani, A.; Zuena, A.R.; Angelucci, L. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J. Neurosci. Res., 2002, 68(3), 337-343.
71. Zhang, Y.; Chun Chen, D.; Long Tan, Y.; Zhou, D.F. A doubleblind, placebo-controlled trial of celecoxib addes to risperidone in first-episode and drug-naive patients with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2006, 256, (Suppl. 2), 2-50.
72. Akhondzadeh, S.; Tabatabaee, M.; Amini, H.; Ahmadi Abhari, S.A.; Abbasi, S.H.; Behnam, B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res., 2007, 90(1/3), 179-185.
73. Rapaport, M.H.; Delrahim, K.K.; Bresee, C.J.; Maddux, R.E.; Ahmadpour, O.; Dolnak, D.; Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry, 2005, 57(12), 1594-1596.
74. Müller, N.; Krause, D.; Dehning, S.; Musil, R.; Schennach-Wolff, R.; Obermeier, M.; Möller, H.J.; Klauss, V.; Schwarz, M.J.; Riedel, M. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res., 2010, 121, 119-124.
75. Müller, N.; Riedel, M.; Schwarz, M.J.; Engel, R.R. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2005, 255(2), 149-151.
76. Cumiskey, D.; Curran, B.P.; Herron, C.E.; O'Connor, J.J. A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus. Neuropharmacology, 2007, 52(8), 1616-1623.
77. Melnikova, T.; Savonenko, A.; Wang, Q.; Liang, X.; Hand, T.; Wu, L.; Kaufmann, W.E.; Vehmas, A.; Andreasson, K.I. Cycloxygenase- 2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sexdimorphic pattern. Neuroscience, 2006, 141(3), 1149-1162.
78. Peet, M.; Brind, J., Ramchand, C.N.; Shah, S.; Vankar, G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res., 2001, 49(3), 243-251.
79. Berger, G.E. Ethyl-eicosapentaenoic acid (E-EPA) supplementation in early psychosis: A double-blind randomised placebo-controlled add on study in 80 drug-naive first episode psychosis patients. Int. J. Neuropsychopharmacol., 2004, 8(Suppl. 1), S422.
80. Fenton, W.S.; Dickerson, F.; Boronow, J., Hibbeln, J.R.; Knable, M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry, 2001, 158(12), 2071-2074.
81. Peet, M.; Horrobin, D.F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res., 2002, 36(1), 7-18.
82. Emsley, R.; Myburgh, C.; Oosthuizen, P.; van Rensburg, S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry, 2002, 159(9), 1596-1598.
83. Bentsen, H. The Norwegian Study on the Treatment of Schizophrenia and Schizoaffective Disorder with EThyl-EPA and Antioxidants: Second Conference on Brain Phospholipids, Aviemore, Scotland, 2006.
84. Emsley, R.; Niehaus, D.J.; Koen, L.; Oosthuizen, P.P.; Turner, H.J.; Carey, P.; van Rensburg, S.J.; Maritz, J.S.; Murck, H. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr. Res., 2006, 84(1), 112-120.
85. Peet, M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr. J. Psychiatry Relat. Sci., 2008, 45(1), 19-25.
86. Rappard, F.; Müller, N. Celecoxib Add-on Therapy Does Not Have Beneficial Antipsychotic Effects Over Risperidone Alone in Schizophrenia. Neuropsychopharmacology, 2004, 29(Suppl. 1), S222.
87. Müller, N.; Schwarz, M.J. Immune System and Schizophrenia. Curr. Immunol. Rev., 2010, 6(3), 213-220.